A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

This trial (CABOTEM) is testing a combination of two drugs — cabozantinib (a targeted therapy) and temozolomide (a chemotherapy drug) — for patients with neuroendocrine tumors (NETs) of the lung or digestive system (GEP-NETs) that have progressed after other treatments like somatostatin analogues, sunitinib, everolimus, or peptide receptor radionuclide therapy (PRRT). **You may be eligible if...** - You are 18 or older with a confirmed neuroendocrine tumor of the lung or gastrointestinal/pancreatic system - Your tumor has progressed after at least one prior therapy - You have measurable disease showing progression on imaging - You have adequate organ function and are in generally good health (ECOG 0–2) - You have had appropriate washout period from prior treatments **You may NOT be eligible if...** - You have previously received temozolomide or cabozantinib - You have active brain metastases (stable, treated ones may be okay) - You have chronic hepatitis B - You have a serious heart condition or prolonged QT interval on ECG - You have had major surgery in the past 3 months - You are pregnant or breastfeeding - You have active serious bleeding, unhealed wounds, or bowel perforation history Talk to your doctor to see if this trial is right for you.